13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001274413
Total reported value
$143.3M
$143.3M
77 檔
27.6%
As reported in its official Q1 2026 Form 13F filing, Sectoral Asset Management Inc's tracked investment portfolio stood at $143.3M with 77 total positions.
In Q1 2026, Sectoral Asset Management Inc adopted a defensive or profit-taking posture, trimming 47 positions and completely liquidating 7 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EVMN | Evommune Inc | Stock-Other | 11.22% | -11.22% | EXIT | |
| 2 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 7.87% | +0.45% | -9.14% | |
| 3 | SI | Shoulder Innovations Inc | Stock-Other | 5.18% | +0.91% | -12.60% | |
| 4 | LLY | Eli Lilly & Co | Stock-Healthcare | 4.84% | +0.48% | -12.67% | |
| 5 | JNJ | Johnson & Johnson | Stock-Healthcare | 3.69% | -0.46% | -10.26% | |
| 6 | GILD | Gilead Sciences Inc | Stock-Healthcare | 3.42% | -1.60% | +53.70% | |
| 7 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 3.35% | +0.49% | +10.02% | |
| 8 | AMGN | Amgen Inc | Stock-Healthcare | 2.91% | -0.58% | -29.53% | |
| 9 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.86% | -0.98% | -12.47% | |
| 10 | INSM | Insmed Inc | Stock-Healthcare | 2.80% | -1.07% | +75.89% | |
| 11 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.27% | -0.44% | +23.15% | |
| 12 | ABBV | Abbvie Inc | Stock-Healthcare | 2.20% | -0.06% | -27.38% | |
| 13 | ABT | Abbott Laboratories | Stock-Healthcare | 2.18% | -1.04% | +8.85% | |
| 14 | MRK | Merck & Co. Inc. | Stock-Healthcare | 2.14% | -0.20% | +0.37% | |
| 15 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 2.06% | -1.12% | -21.43% | |
| 16 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.00% | -0.38% | +8.25% | |
| 17 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.81% | -0.73% | +25.90% | |
| 18 | BNTX | Biontech Se-adr | Stock-Other | 1.69% | +1.03% | +28.73% | |
| 19 | SYK | Stryker CORP | Stock-Healthcare | 1.60% | -0.03% | -10.32% | |
| 20 | DHR | Danaher CORP | Stock-Healthcare | 1.51% | -0.23% | -9.25% | |
| 21 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.43% | -0.20% | -10.05% | |
| 22 | DXCM | Dexcom Inc | Stock-Healthcare | 1.21% | +1.18% | -19.06% | |
| 23 | IQV | Iqvia Holdings Inc | Stock-Healthcare | 1.17% | +0.29% | — | |
| 24 | SMMT | Summit Therapeutics Inc | Stock-Other | 1.16% | +1.08% | -12.57% | |
| 25 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.15% | -0.21% | +0.51% | |
| 26 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 1.06% | -0.21% | — | |
| 27 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.95% | -0.43% | -0.75% | |
| 28 | VERA | Vera Therapeutics Inc | Stock-Other | 0.90% | -0.13% | -30.62% | |
| 29 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.86% | +1.53% | -20.85% | |
| 30 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.84% | +0.67% | -28.33% | |
| 31 | MDT | Medtronic plc | Stock-Healthcare | 0.80% | -0.19% | — | |
| 32 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.78% | +0.07% | -11.64% | |
| 33 | COGT | Cogent Biosciences Inc | Stock-Other | 0.75% | -0.03% | -32.26% | |
| 34 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.74% | -0.47% | -0.02% | |
| 35 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.72% | -0.23% | -22.74% | |
| 36 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.71% | -0.13% | -23.53% | |
| 37 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.69% | -0.69% | EXIT | |
| 38 | NKTR | Nektar Therapeutics | Stock-Other | 0.68% | -0.19% | -19.53% | |
| 39 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.65% | -0.41% | -48.24% | |
| 40 | ARDX | Ardelyx Inc | Stock-Other | 0.65% | -0.21% | — | |
| 41 | PFE | Pfizer Inc | Stock-Healthcare | 0.64% | -0.18% | +1.29% | |
| 42 | BOLD | Boundless Bio Inc | Stock-Other | 0.62% | -0.62% | EXIT | |
| 43 | ASND | Ascendis Pharma A/S | Stock-Other | 0.60% | -0.60% | EXIT | |
| 44 | AVBP | Arrivent Biopharma Inc | Stock-Other | 0.60% | +1.32% | -21.54% | |
| 45 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.59% | -0.43% | -40.93% | |
| 46 | ✓ | Immatics NV | Stock-Other | 0.57% | +1.02% | +6.05% | |
| 47 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.57% | -0.36% | -27.48% | |
| 48 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.56% | -0.39% | +165.58% | |
| 49 | ONC | Beone Medicines Ltd-adr | Stock-Other | 0.52% | -0.15% | -29.83% | |
| 50 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.52% | +1.18% | -54.90% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | EVMN | Evommune Inc | +3.1% | — | Unchanged |
| 2 | GILD | Gilead Sciences Inc | +1.7% | +53.70% | Add |
| 3 | INSM | Insmed Inc | +1.2% | +75.89% | Add |
| 4 | CTNM | Contineum Therapeutics Inc-a | +0.5% | -9.14% | Trim |
| 5 | BNTX | Biontech Se-adr | +0.4% | +28.73% | Add |
| 6 | MRK | Merck & Co. Inc. | +0.3% | +0.37% | Add |
| 7 | ARGX | Argenx Se - Adr | +0.3% | +23.15% | Add |
| 8 | JNJ | Johnson & Johnson | +0.3% | -10.26% | Trim |
| 9 | SPRY | Ars Pharmaceuticals Inc | +0.3% | +165.58% | Add |
| 10 | UTHR | United Therapeutics CORP | +0.3% | -0.75% | Trim |
| 11 | NKTR | Nektar Therapeutics | +0.2% | -19.53% | Trim |
| 12 | CYTK | Cytokinetics Inc | +0.2% | +23.88% | Add |
| 13 | ORIC | Oric Pharmaceuticals Inc | +0.1% | +4.54% | Add |
| 14 | PFE | Pfizer Inc | +0.1% | +1.29% | Add |
| 15 | MRNA | Moderna Inc | +0.1% | -13.09% | Trim |
| 16 | RPRX | Royalty Pharma plc | +0.1% | -14.99% | Trim |
| 17 | KURA | Kura Oncology Inc | +0.1% | +32.10% | Add |
| 18 | ROIV | Roivant Sciences Ltd. | +0.1% | -28.33% | Trim |
| 19 | ASND | Ascendis Pharma A/S | 0% | -13.95% | Trim |
| 20 | ✓ | Immatics NV | 0% | +6.05% | Add |
| 21 | SMMT | Summit Therapeutics Inc | 0% | -12.57% | Trim |
| 22 | JAZZ | Jazz Pharmaceuticals plc | 0% | -14.59% | Trim |
| 23 | BIIB | Biogen Inc | 0% | -14.15% | Trim |
| 24 | ILMN | Illumina Inc | 0% | -13.75% | Trim |
| 25 | AXSM | Axsome Therapeutics Inc | 0% | -13.79% | Trim |
| 26 | INCY | Incyte CORP | 0% | -14.55% | Trim |
| 27 | AVBP | Arrivent Biopharma Inc | 0% | -21.54% | Trim |
| 28 | IONS | Ionis Pharmaceuticals Inc | 0% | -13.93% | Trim |
| 29 | BMRN | Biomarin Pharmaceutical Inc | 0% | -13.14% | Trim |
| 30 | NBIX | Neurocrine Biosciences Inc | 0% | -14.02% | Trim |
| 31 | EW | Edwards Lifesciences CORP | 0% | +0.51% | Add |
| 32 | BOLD | Boundless Bio Inc | 0% | — | Unchanged |
| 33 | PRVA | Privia Health Group Inc | 0% | +4.37% | Add |
| 34 | PTCT | Ptc Therapeutics Inc | 0% | -13.80% | Trim |
| 35 | VRTX | Vertex Pharmaceuticals Inc | -0.1% | -12.47% | Trim |
| 36 | TRVI | Trevi Therapeutics Inc | -0.1% | -11.64% | Trim |
| 37 | BBIO | Bridgebio Pharma Inc | -0.1% | -27.48% | Trim |
| 38 | ALHC | Alignment Healthcare Inc | -0.1% | -14.57% | Trim |
| 39 | ONC | Beone Medicines Ltd-adr | -0.1% | -29.83% | Trim |
| 40 | HNGE | Hinge Health Inc-a | -0.1% | -13.81% | Trim |
| 41 | ABT | Abbott Laboratories | -0.2% | +8.85% | Add |
| 42 | COGT | Cogent Biosciences Inc | -0.2% | -32.26% | Trim |
| 43 | MLYS | Mineralys Therapeutics Inc | -0.2% | -0.02% | Trim |
| 44 | QURE | uniQure N.V. | -0.2% | -4.38% | Trim |
| 45 | OMDA | Omada Health Inc | -0.2% | -29.81% | Trim |
| 46 | TECX | Tectonic Therapeutic Inc | -0.2% | -54.90% | Trim |
| 47 | ISRG | Intuitive Surgical Inc | -0.2% | +8.25% | Add |
| 48 | INSP | Inspire Medical Systems Inc | -0.2% | +0.35% | Add |
| 49 | ALNY | Alnylam Pharmaceuticals Inc | -0.2% | -22.74% | Trim |
| 50 | RCUS | Arcus Biosciences Inc | -0.2% | -20.85% | Trim |
According to official SEC Form 13F filings, Sectoral Asset Management Inc reported a total U.S. public equity portfolio value of $143.3M across 77 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including EVMN, CTNM, SI) accounted for 27.6% of total reported equity market value during Q1 2026.
Top New Position Initiated
IQV
市值: $1.4M
Top Position Liquidated / Trimmed
AZNN
前期市值: $1.4M
During Q1 2026, Sectoral Asset Management Inc's top holdings by market value included EVMN (11.2%)、CTNM (7.9%)、SI (5.2%). The largest single position, EVMN, represented 11.2% of total portfolio value.
In Q1 2026, Sectoral Asset Management Inc made 82 total portfolio adjustments, initiating 10 new buys, adding to 18 positions, trimming 47 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.